R&D evidence
Prepare technical milestones, experimental records, regulatory pathway and expenditure timing.
Biotech & Medtech R&D funding
Plan liquidity around the R&D cycle, not just the tax-return date.
For companies undertaking clinical, laboratory, device, diagnostic and health-technology development, R&D expenditure can occur well before an anticipated tax benefit is received. SME Capital Partners is developing $100,000–$1 million business-purpose R&D facilities, subject to assessment, evidence and final terms.
Expenditure profile
Map specialist staff, laboratories, trials, prototypes, testing and external research costs against the company's cash runway.
Whole-company capacity
The anticipated R&D position is only one part of a commercial credit assessment; revenue, liquidity, liabilities and repayment capacity also matter.
R&DTI remains a self-assessment program
The Australian Government states that companies are responsible for assessing their entity, activity and expenditure eligibility. Registration confirmation does not itself mean activities are eligible.
Registration timing matters
Companies generally need to apply to register eligible activities within 10 months after the end of the income year in which the activities occurred. Applicants should confirm current requirements with the program and their advisers.
Funding is separate commercial credit
An SME Capital Partners facility would not be an R&DTI determination, tax ruling, government advance or guarantee of a tax outcome.
Official source
General information only. This page does not constitute legal, tax, financial or credit advice. SME Capital Partners is in pre-launch and is not currently offering or approving credit through this website.